CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, forced expression of miR-34a sensitizes CD34+ CML cells to imatinib mesylate, a tyrosine kinase inhibitor (TKI) (Rothe et al., 2014).